Main > ONCOLOGY (**) > Lymphoma>NHL>B-Cell>FL R/R>*** > TREAT.: > USA. G. CD20xCD3 BiSpecific MAb>

---

USA. G. CD20xCD3 BiSpecific MAb>'s subsections
(*) EU Approval Date: 2022. 06.09
(*) USA Approval Date: 2022. 12.22
>Injection for IV Use
Company
Generic Name
TM
TM Web-Site USA
USA Patent APP. Numbers

USA. G. CD20xCD3 BiSpecific MAb>'s products
This section has no products